Latest Leadership Changes News

Alterity Therapeutics posted a 285% jump in revenue to A$1.72 million but also a 93% rise in net loss to A$23.4 million for FY2026. The company secured FDA alignment on a single pivotal Phase 3 trial for ATH434 in Multiple System Atrophy, setting the stage for trial start by year-end.

HITIQ Limited posted a 21% drop in revenue to $1.59 million and reduced its net loss by 15% to $6.1 million for FY26, advancing commercialisation of its concussion management platform PROTEQT™ despite ongoing funding pressures and regulatory hurdles.

Mirrabooka Investments posted a 63.6% profit increase to $13 million for FY26 but saw its portfolio return lag the benchmark. The company declared a 14 cents fully franked dividend and welcomed Alison Gibson as new CEO following Mark Freeman's retirement.

Kip McGrath Education Centres reversed prior losses with a $2.5 million profit in FY26 despite a 4.3% revenue dip driven by franchise consolidation and foreign exchange headwinds. The company declared a special dividend and faces an unsolicited $0.73 per share takeover offer.

Critical Minerals Group names COO Pat Kelly as interim CEO following Scott Winter's resignation to lead BTP. The company confirms its strategy and Lindfield Vanadium Project plans remain steady during the transition.

Micro-X Limited lifted revenues by 16% to $15.1 million for FY26 but posted a $9.9 million net loss, narrowing from the prior year. The company advanced key medical imaging milestones and initiated a strategic reset to sharpen commercial focus and reduce costs.

Synlait Milk anticipates a modest improvement in underlying EBITDA for FY26 but expects a substantial net loss after tax, reflecting ongoing operational challenges and a tough first half.

Air New Zealand reported a $242 million net loss after tax for FY2026, hit by soaring fuel costs linked to the Middle East conflict and persistent engine issues. The airline unveiled a new strategy aiming for operational resilience and targeted growth amid ongoing cost pressures.

Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.

Industrial Minerals Ltd has finalised its takeover of Galleon Metals, adding a 205km² gold exploration portfolio in WA’s Eastern Goldfields. The company also announced key board appointments, including a new Managing Director with direct Laverton expertise.

Careteq Limited (ASX: CTQ) reported a $398K net loss for FY26 amid a strategic reset that included selling its Embedded Health Solutions business and repaying all debt. The company now pivots fully to growing its HMR Referrals platform with $3.19 million cash on hand.

ImpediMed reported a 15% revenue increase to $14.6 million in FY26, broadened reimbursement coverage for its SOZO platform to 95% of the US population, and launched new applications in heart health and weight management.